Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.68 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955739 | 0.91 | SLC22A12 (0.57) | SLC22A12PLA2G4BFFAR1LTB4RLTB4R2 | |
| SCHEMBL1719090 | 0.87 | SLC22A12 (0.52) | SLC22A12FFAR1LTB4RLTB4R2MAOB | |
| SCHEMBL956735 | 0.86 | FFAR1 (0.62) | SLC22A12FFAR1 | |
| SCHEMBL954556 | 0.85 | SLC22A12 (0.68) | SLC22A12FFAR1PPARD | |
| SCHEMBL1718777 | 0.85 | SLC22A12 (0.50) | SLC22A12LTB4RLTB4R2 | |
| SCHEMBL1010327 | 0.85 | SLC22A12 (0.50) | SLC22A12LTB4RLTB4R2MAOB | |
| SCHEMBL1760801 | 0.84 | PPARD (0.49) | SLC22A12PLA2G4BFFAR1LTB4RLTB4R2 | |
| SCHEMBL954242 | 0.83 | FFAR1 (0.54) | SLC22A12FFAR1 | |
| SCHEMBL955388 | 0.83 | SLC22A12 (0.51) | SLC22A12PLA2G4BLTB4RLTB4R2PPARD | |
| SCHEMBL954459 | 0.83 | NR4A2 (0.66) | FFAR1LTB4RLTB4R2MAOBNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| EP-1601251-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2014-11-12 | — | — | EP | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| US-20130137629-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| US-8338480-B2 | Combination treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | claimed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | claimed |
| EP-2056673-A2 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2009-05-13 | — | — | EP | claimed |
| EP-2001461-A2 | COMBINATION TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2008022267-A2 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-02-21 | — | — | WO | claimed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | claimed |
| WO-2007117791-A2 | COMBINATION TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | WO | claimed |
| EP-1601251-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | claimed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | SLC22A12 1447/4885PLA2G4B 3967/4885FFAR1 5/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | SLC22A12 139/4885PLA2G4B 3326/4885FFAR1 5/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | SLC22A12 908/4885PLA2G4B 3210/4885FFAR1 6/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | SLC22A12 257/4885PLA2G4B 3332/4885FFAR1 513/4885 |
| US-20130137629-A1 | COMBINATION TREATMENT FOR METABOLIC DISORDERS | DPP8, GLP1R, GPR119 | SLC22A12 2793/4885PLA2G4B 3233/4885FFAR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.